Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Richard Adams, Ewan Brown, Louise Brown, Rachel Butler, Stephen Falk, David Fisher, Richard Kaplan, Phil Quirke, Susan Richman, Leslie Samuel, Jenny Seligman, Matt Seymour, Kai Keen Shui, Harpreet Wasan, Richard Wilson, Tim Maughan

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)
7 Downloads (Pure)
Original languageEnglish
Pages (from-to)162–171
Number of pages9
JournalThe Lancet Gastroenterology & Hepatology
Issue number3
Early online date15 Dec 2017
Publication statusPublished - Mar 2018


  • colorectal cancer
  • biomarkers
  • therapeutic efficacy
  • EGFR inhibitors

Cite this